Company intelligence / Profile preview
Anodyne Nanotech
Boston, Massachusetts, United Statestheheropatch.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Anodyne Nanotech has demonstrated preclinical efficacy for its APJ receptor agonist program in sarcopenia using the HeroPatch microneedle system. The company’s lead asset—a once-weekly transdermal GLP‑1 patch for obesity—is expected to enter clinical trials in 2026. Their technology enables non-invasive delivery of biologics and peptides with potential benefits over injections[1].
- Therapeutic areas
- Metabolic DisordersOncologyEndocrinologyImmunology
- Modalities
- BiologicPeptidesSmall moleculeMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Early collaborations with leading pharmaceutical partners
Beyond the preview
Go deeper on Anodyne Nanotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anodyne Nanotech.